
|Articles|May 15, 2005
Glaucoma combo solution earns preliminary approval
The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.
Advertisement
The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.
The company said it would meet with the FDA to clarify what steps are yet required to gain final marketing approval.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
3
Study links alcohol consumption to earlier advanced presbyopia in men
4
Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)
5





















